Tadalafil
Product Images NDC 50436-0114

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50436-0114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl504360114

Tadalafil 20 mg tablets unit dose packaging label from Unit Dose Services. The label states prescription use only and includes packaging information for one tablet per unit dose pouch, with 200 pouches per case. It provides storage instructions, warnings to keep out of reach of children, and manufacturer details including Ajanta Pharma USA Inc.*

FDA Label Image

Label Image (Lbl504361120)

Tadalafil 5 mg tablets label from Unit Dose Services. The label states prescription use only (RX ONLY), with dosage form as film-coated tablets. Packaging includes one tablet per unit dose pouch, with 200 pouches per case. Storage instructions specify 20-25°C with allowed excursions. Marketed by Ajanta Pharma USA Inc. and repackaged by Unit Dose Services, LLC. The label includes barcode, NDC number 50436-1120-1, warnings, and contact information for questions or comments.*

FDA Label Image

Figure01 (Tadalafil Figure1)

A set of four line graphs showing differences in blood pressure over time, titled Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP. The y-axes display difference in mmHg (Tadalafil minus placebo), and the x-axes denote time in hours up to 96. Each graph includes error bars for variability at measured points.*

FDA Label Image

Figure02 (Tadalafil Figure2)

A two-panel line graph showing the effects on standing and supine systolic blood pressure (BP) over 24 hours post-dose. The top panel displays standing systolic BP and the bottom panel supine systolic BP. The graph compares Tadalafil 20 mg combined with doxazosin 8 mg against placebo with doxazosin 8 mg. Time post-dose (hours) is on the x-axis, and systolic BP change (mmHg) is on the y-axis.*

FDA Label Image

Figure03 (Tadalafil Figure3)

A line graph displaying systolic blood pressure (mmHg) over time (hours) after administration of tadalafil or placebo, combined with doxazosin. The graph compares four groups: tadalafil 20 mg at 08:00 with doxazosin 8 mg, placebo at 08:00 with doxazosin 8 mg, tadalafil 20 mg at 20:00 with doxazosin 8 mg, and placebo at 20:00 with doxazosin 8 mg, illustrating blood pressure changes post-dose.*

FDA Label Image

Figure04 (Tadalafil Figure4)

A pharmacokinetic graph showing plasma tadalafil concentration (µg/L) versus time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph illustrates changes in tadalafil concentration over a 120-hour period with error bars.*

FDA Label Image

Figure05 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment duration. Two groups are compared: Tadalafil 5 mg and placebo. The Tadalafil group shows a greater reduction in score over time, with statistically significant differences (p<0.01) at measured intervals.*

FDA Label Image

Figure06 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment. It plots results for Tadalafil 5 mg versus placebo, showing a decrease in score for Tadalafil throughout the treatment duration. The graph includes data points at weeks 0, 1, 4, and 12, with a statistical significance indicator (p<0.01).*

FDA Label Image

Figure07 (Tadalafil Figure7)

A line graph showing least-squares mean change from baseline in efficacy over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows change from baseline with values decreasing to -7.0. Significant differences (p<0.001 and p<0.05) between groups are indicated at weeks 4, 12, and 26.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of the active ingredient Tadalafil, showing its molecular framework including multiple rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.